%0 Journal Article
%A Ceccon, Garry
%A Lazaridis, Lazaros
%A Stoffels, Gabriele
%A Rapp, Marion
%A Weber, Manuel
%A Blau, Tobias
%A Lohmann, Phillip
%A Kebir, Sied
%A Herrmann, Ken
%A Fink, Gereon R.
%A Langen, Karl-Josef
%A Glas, Martin
%A Galldiks, Norbert
%T Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience
%J European journal of nuclear medicine and molecular imaging
%V 45
%N 9
%@ 1619-7089
%C Heidelberg [u.a.]
%I Springer-Verl.
%M FZJ-2018-02172
%P 1626 - 1635
%D 2018
%X PurposeWe present our first clinical experience with O-(2-18F-fluoroethyl)-l-tyrosine (FET) PET in patients with high-grade glioma treated with various neurooncological therapies including tumour-treating fields (TTFields) for the differentiation of tumour progression from treatment-related changes.MethodsWe retrospectively assessed 12 patients (mean age 51 ± 12 years, range 33–72 years) with high-grade glioma (11 glioblastomas, 1 gliosarcoma) in whom the treatment regimen included TTFields and who had undergone FET PET scans for differentiation of tumour progression from treatment-related changes. Mean and maximum tumour-to-brain ratios (TBRmean, TBRmax) were calculated. The definitive diagnosis (tumour progression or posttherapeutic changes) was confirmed either by histopathology (4 of 12 patients) or on clinical follow-up.ResultsIn all nine patients with confirmed tumour progression, the corresponding FET PET showed increased uptake (TBRmax 3.5 ± 0.6, TBRmean 2.7 ± 0.7). In one of these nine patients, FET PET was consistent with treatment-related changes, whereas standard MRI showed a newly diagnosed contrast-enhancing lesion. In two patients treated solely with TTFields without any other concurrent neurooncological therapy, serial FET PET revealed a decrease in metabolic activity over a follow-up of 6 months or no FET uptake without any signs of tumour progression or residual tumour on conventional MRI.ConclusionFET PET may add valuable information in monitoring therapy in individual patients with high-grade glioma undergoing neurooncological treatment including TTFields.
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:29564490
%U <Go to ISI:>//WOS:000437733300016
%R 10.1007/s00259-018-3992-5
%U https://juser.fz-juelich.de/record/844796